61 phenotypes from 8 alleles in 6 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cyldtm1.1Awai/Cyldtm1.1Awai Not Specified	abnormal B cell differentiation	J:126113
	abnormal B cell morphology	J:126113
	abnormal B cell physiology	J:126113
	abnormal class switch recombination	J:126113
	abnormal humoral immune response	J:126113
	abnormal Peyer's patch germinal center morphology	J:126113
	abnormal spleen marginal zone morphology	J:126113
	abnormal spleen morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased IgG3 level	J:126113
	decreased IgM level	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
	increased follicular B cell number	J:126113
	increased IgA level	J:126113
	increased IgG1 level	J:126113
	increased IgG2a level	J:126113
	increased IgG2b level	J:126113
	increased marginal zone B cell number	J:126113
	increased pro-B cell number	J:126113
Cyldtm1.1Gmos/Cyldtm1.1Gmos involves: BALB/cJ	abnormal lung development	J:162840
	abnormal lung interstitium morphology	J:162840
	abnormal respiratory function	J:162840
	atelectasis	J:162840
	cyanosis	J:162840
	decreased birth body size	J:162840
	impaired fibroblast cell migration	J:162840
	kinked tail	J:162840
	neonatal lethality, complete penetrance	J:162840
	short tail	J:162840
	small lung	J:162840
	thick lung-associated mesenchyme	J:162840
Cyldtm1Awai/Cyldtm1Awai Tg(CD19-cre/ERT2)1Cgn/? Not Specified	abnormal mature B cell morphology	J:126113
	decreased B-1 B cell number	J:126113
	decreased immature B cell number	J:126113
	enlarged lymph nodes	J:126113
	enlarged Peyer's patches	J:126113
	enlarged spleen	J:126113
	increased B cell number	J:126113
Cyldtm1Gmos/Cyldtm1Gmos Not Specified	no abnormal phenotype detected	J:162840
Cyldtm1Jdgl/Cyldtm1Jdgl involves: 129 * C57BL/6J	decreased susceptibility to bacterial infection	J:124327
	decreased susceptibility to bacterial infection induced morbidity/mortality	J:124327
Cyldtm1Lex/Cyldtm1Lex involves: 129S5/SvEvBrd * C57BL/6	abnormal circulating serum albumin level	J:114972
	abnormal colon morphology	J:114972
	abnormal inflammatory response	J:114972
	abnormal intestinal epithelium morphology	J:114972
	gastric ulcer	J:114972
	hunched posture	J:114972
	normal immune system phenotype	J:114972
	increased incidence of tumors by chemical induction	J:114972
	increased susceptibility to induced colitis	J:114972
	premature death	J:114972
	thymus hyperplasia	J:114972
	weight loss	J:114972
Cyldtm1Ref/Cyld+ B6.129-Cyldtm1Ref	increased skin papilloma incidence	J:108769
Cyldtm1Ref/Cyldtm1Ref B6.129-Cyldtm1Ref	abnormal keratinocyte proliferation	J:108769
	epidermal hyperplasia	J:108769
	increased cell proliferation	J:108769
	increased keratinocyte proliferation	J:108769
	increased skin papilloma incidence	J:108769
Cyldtm1Ref/Cyldtm1Ref Not Specified	normal immune system phenotype	J:126113
Cyldtm1Scs/Cyldtm1Scs involves: 129S1/Sv * 129X1/SvJ	abnormal B cell differentiation	J:112392
	abnormal enzyme/coenzyme activity	J:112392
	abnormal T cell number	J:112392
	decreased CD4-positive, alpha-beta T cell number	J:112392
	decreased CD8-positive, alpha-beta T cell number	J:112392
	increased double-positive T cell number	J:112392